Trulieve Cannabis (CSE: TRUL) announced that they will be reporting their first quarter financials before market open on March 13th. Analysts have a consensus C$88.08 12-month price target on the company, via a total of 15 analysts, with four analysts having a strong buy rating and the other 11 have buy ratings. The street high comes from Stifel-GMP with a C$118 price target, and the lowest target comes from Cantor Fitzgerald with a C$71 price target.
Twelve analysts have revenue estimates for the first quarter. The mean between all 14 is U$188.78 million; this number has been revised slightly upwards from U$184.33 million at the start of the year. PI Financial currently has the highest revenue estimate with U$201 million, while the lowest comes from Stifel-GMP with a U$185.21 million estimate.
Six analysts has estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 70.75%, with this number being revised upwards from 68.33% at the start of the year. Street high goes to Stifel-GMP with a 72.50% estimate and the lowest sits at 68%.
Onto EBITDA estimates, there are currently 12 analysts who have first quarter EBITDA estimates. The mean is currently U$83.83 million, with this number being similar to what it was at the start of the year. Street high goes to Cantor Fitzgerald with a U$87.40 million EBITDA estimate and the lowest being from Haywood with a U$76.40 million estimate.
Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
